Evidence map›Paper›PMID 34518512›Full record

ArticleCell death & disease2021

CXCL13/CXCR5 axis facilitates endothelial progenitor cell homing and angiogenesis during rheumatoid arthritis progression.

Chun-Hao Tsai, Chao-Ju Chen, Chi-Li Gong, Shan-Chi Liu, Po-Chun Chen, Chien-Chung Huang, Sung-Lin Hu, Shih-Wei Wang, Chih-Hsin Tang

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 55 citations in OpenAlex.

  1. A Versatile Anti-CXCR5 Monoclonal Antibody (CxCurrent issues in molecular biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Endothelial progenitor cells and chronic obstructive pulmonary disease: From basic research to clinical application.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chun-Hao TsaiDepartment of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan.
Chao-Ju ChenSchool of Medicine, China Medical University, Taichung, Taiwan.
Chi-Li GongSchool of Medicine, China Medical University, Taichung, Taiwan.
Shan-Chi LiuDepartment of Medical Education and Research, China Medical University Beigang Hospital, Yunlin, Taiwan.
Po-Chun ChenTranslational Medicine Center, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Chien-Chung HuangSchool of Medicine, China Medical University, Taichung, Taiwan.
Sung-Lin HuSchool of Medicine, China Medical University, Taichung, Taiwan.
Shih-Wei WangDepartment of Medicine, MacKay Medical College, New Taipei City, Taiwan.ORCID 0000-0001-7522-6352
Chih-Hsin TangSchool of Medicine, China Medical University, Taichung, Taiwan. chtang@mail.cmu.edu.tw.ORCID 0000-0002-7113-8352
China Medical University · TWAsia University · TWKaohsiung Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiogenesis is a critical process in the formation of new capillaries and a key participant in rheumatoid arthritis (RA) pathogenesis. The chemokine (C-X-C motif) ligand 13 (CXCL13) plays important roles in several cellular functions such as infiltration, migration, and motility. We report significantly higher levels of CXCL13 expression in collagen-induced arthritis (CIA) mice compared with controls and also in synovial fluid from RA patients compared with human osteoarthritis (OA) samples. RA synovial fluid increased endothelial progenitor cell (EPC) homing and angiogenesis, which was blocked by the CXCL13 antibody. By interacting with the CXCR5 receptor, CXCL13 facilitated vascular endothelial growth factor (VEGF) expression and angiogenesis in EPC through the PLC, MEK, and AP-1 signaling pathways. Importantly, infection with CXCL13 short hairpin RNA (shRNA) mitigated EPC homing and angiogenesis, articular swelling, and cartilage erosion in ankle joints of mice with CIA. CXCL13 is therefore a novel therapeutic target for RA.

Indexed as

Disease ProgressionNeovascularization, PhysiologicAnimalsArthritis, RheumatoidButadienesCell MembraneCell MovementChemokine CXCL13Endothelial Progenitor CellsEstrenesHumansMiceMice, Inbred C57BLModels, BiologicalNitrilesProto-Oncogene Proteins c-jun1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dioneButadienesChemokine CXCL13CXCL13 protein, humanCXCR5 protein, humanEstrenesNitrilesProto-Oncogene Proteins c-junPyrrolidinonesReceptors, CXCR5RNA, Small InterferingTranscription Factor AP-1U 0126Vascular Endothelial Growth Factor A

Identifiers

PMID34518512
PMCPMC8437941
OpenAlexW3199165731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.